In 23 previously non-responder patients with chronic hepatitis C, a triple regimen of peginterferon alfa-2a, ribavirin and thymalfasin gave a viral response of 60.8% at week 12.
In plain wordsIn hepatitis C patients who had not responded before, a three-drug regimen including thymalfasin gave a viral response of 60.8% at week 12.
- Peptide
- Thymosin alpha-1
- Outcome
- Not applicableViral response at week 12
- Study
n = 23
- Outcome group
- Antiviral activity · Infection
Measurements
- Viral response
- 60.8%
- week 12
Source sentences
Viral response was 60.8% at week 12 and 47.8% at week 24.
1 context sentence(design, population, supporting numbers)
Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups: one such triple therapy regimen is peginterferon alfa-2a, ribavirin and thymalfasin, which was given to 23 previously non-responder patients.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.